Literature DB >> 15961981

Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein beta3 subunit gene (GNB3).

Anna Mitchell1, Mutlu Pace, Jens Nürnberger, René R Wenzel, Winfried Siffert, Thomas Philipp, Rafael F Schäfers.   

Abstract

OBJECTIVE: A C825T polymorphism has been identified for the gene encoding the G-protein beta 3 subunit ( GNB3 ). The 825T allele is associated with hypertension and obesity, which in turn are closely linked with resistance to the metabolic and vascular effects of insulin. We hypothesized that venodilation in response to insulin would be impaired in GNB3 825T-allele carriers. Because vasodilatory properties of insulin are mainly mediated by nitric oxide, we also investigated the influence of the T-786C polymorphism of the gene for endothelial nitric oxide synthase ( NOS3 ) on insulin-mediated venous responses.
METHODS: We used the linear variable transducer technique to compare dorsal hand vein compliance in 31 young, healthy men ( GNB3 C825T: 15 CC, 14 CT, and 2 TT; NOS3 T-786C: 14 TT, 13 TC, and 4 CC). Individual dose-response curves to phenylephrine (3.2-10,000 ng/min) were established, and veins were preconstricted by a constant infusion of phenylephrine at the individual dose needed to procure 70% of maximal constriction. Then insulin was infused (50-250,000 microU/min), and the changes in venous diameter were recorded.
RESULTS: Venous response to insulin was biphasic, with venoconstriction at low doses being followed by venodilation at higher doses. Insulin dose-response curves of GNB3 825T-allele carriers were significantly shifted to the right (ANOVA, P < .001, versus CC). NOS3 T-786C-allele carrier status had no influence on insulin-induced vascular responses ( P = .60 for TC/CC versus TT).
CONCLUSION: This study is the first to show the influence of a genetic polymorphism on insulin-mediated venodilation in men in vivo. Further studies are needed to determine whether these results translate to other vascular beds, and possible gender-specific differences remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961981     DOI: 10.1016/j.clpt.2005.03.002

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant.

Authors:  Marcus Dörr; Carsten O Schmidt; Thomas Spielhagen; Alexa Bornhorst; Katharina Hentschel; Christina Franz; Klaus Empen; Thomas Kocher; Scott R Diehl; Heyo K Kroemer; Henry Völzke; Ralf Ewert; Stephan B Felix; Dieter Rosskopf
Journal:  Pharmacogenomics       Date:  2010-09       Impact factor: 2.533

Review 2.  Update on G-protein polymorphisms in hypertension.

Authors:  Haidong Zhu; Xiaoling Wang; Yanhui Lu; Joseph Poola; Zamena Momin; Gregory A Harshfield; Harold Snieder; Yanbin Dong
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 3.  Genetics of arterial hypertension and hypotension.

Authors:  Dieter Rosskopf; Markus Schürks; Christian Rimmbach; Rafael Schäfers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-30       Impact factor: 3.000

Review 4.  Subtype-dependent regulation of Gβγ signalling.

Authors:  Mithila Tennakoon; Kanishka Senarath; Dinesh Kankanamge; Kasun Ratnayake; Dhanushan Wijayaratna; Koshala Olupothage; Sithurandi Ubeysinghe; Kimberly Martins-Cannavino; Terence E Hébert; Ajith Karunarathne
Journal:  Cell Signal       Date:  2021-02-11       Impact factor: 4.850

5.  Effects of interacting networks of cardiovascular risk genes on the risk of type 2 diabetes mellitus (the CODAM study).

Authors:  Marleen M J van Greevenbroek; Jian Zhang; Carla J H van der Kallen; Paul M H Schiffers; Edith J M Feskens; Tjerk W A de Bruin
Journal:  BMC Med Genet       Date:  2008-04-24       Impact factor: 2.103

6.  G protein beta 3(GNβ3) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies.

Authors:  Dongbo Jiang; Dong Huang; Weiming Cai; Ting Li; Yan Wang; Huayan Chen; Tangming Guan; Xiaoli Ma
Journal:  Oncotarget       Date:  2017-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.